

Biota Holdings Limited

ACN 006 479 081

10/585 Blackburn Road
Notting Hill VIC 3168
Australia**T** +61 3 9915 3700**F** +61 3 9915 3702**E** info@biota.com.au**W** www.biota.com.au*For Immediate Release*

Melbourne, Australia — 11 November 2010

Shares released from escrow

Biota Holdings Limited (ASX:BTA) acquired the antibacterial assets of Prolysis Limited on 12 November 2009. As outlined in the ASX announcement of that date and pursuant to the Asset Acquisition Agreement, 2,391,144 shares issued as consideration were subject to a 12 month escrow period.

Instructions have been given to the Share Registry to release the shares from escrow.

About Biota

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product Inavir[®], is approved for marketing in Japan.

Relenza[™] is a registered trademark of the GlaxoSmithKline group of companies.

*Further information available at www.biota.com.au

Investor / Analyst Enquiries**Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

Media Enquiries

Jo Lynch, Hinton & Associates

T: +61 3 9600 1979 / M: +61 411 208 101

US Enquiries

Remy Bernarda, Blueprint Life Science Group

M: +1 415 203 6386